Inhibition of poly(ADP-ribose) polymerase-1 or poly(ADP‑ribose) glycohydrolase individually, but not in combination, leads to improved chemotherapeutic efficacy in HeLa cells

Feng,Xiaoxing; Koh,David  W.

doi:10.3892/ijo.2012.1740

Inhibition of poly(ADP-ribose) polymerase-1 or poly(ADP‑ribose) glycohydrolase individually, but not in combination, leads to improved chemotherapeutic efficacy in HeLa cells

Authors:
- Xiaoxing Feng
- David W. Koh
View Affiliations

Affiliations: Department of Pharmaceutical Sciences, College of Pharmacy, Washington State University, Pullman, WA 99164-6534, USA
Published online on: December 17, 2012 https://doi.org/10.3892/ijo.2012.1740
Pages: 749-756

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The genome-protecting role of poly(ADP-ribose) (PAR) has identified PAR polymerase-1 (PARP-1) and PAR glycohydrolase (PARG), two enzymes responsible for the synthesis and hydrolysis of PAR, as chemotherapeutic targets. Each has been previously individually evaluated in chemotherapy, but the effects of combination PARP-1 and PARG inhibition in cancer cells are not known. Here we determined the effects of the inhibition of PARP-1 and the absence or RNAi knockdown of PARG on PAR synthesis, cell death after chemotherapy and long-term viability. Using three experimental/clinical PARP-1 inhibitors in PARG-null cells, we show decreased levels of PAR and increased short‑term and long‑term viability with each inhibitor, with the exception of DPQ. Treatment with the experimental chemotherapeutic agent, N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), led to increased cell death in PARG-null cells, but decreased cell death when pretreated with each PARP-1 inhibitor. Similar results were observed in MNNG-treated HeLa cells, where RNAi knockdown of PARG or pretreatment with ABT-888 led to increased HeLa cell death, whereas combination PARG RNAi knockdown + ABT-888 failed to produce increased cell death. The results demonstrate the ability of the PARP-1 inhibitors to decrease PAR levels, maintain viability and decrease PAR-mediated cell death after chemotherapeutic treatment in the absence of PARG. Further, the results demonstrate that the combination of PARP-1 and PARG inhibition in chemotherapy does not produce increased HeLa cell death. Thus, the results indicate that inhibiting both PARP-1 and PARG, which both are chemotherapeutic targets that increase cancer cell death, does not lead to synergistic cell death in HeLa cells. Therefore, strategies that target PAR metabolism for the improved treatment of cancer may be required to target PARP-1 and PARG individually in order to optimize cancer cell death.

View Figures

View References

1.	Wang ZQ, Stingl L, Morrison C, et al: PARP is important for genomic stability but dispensable in apoptosis. Genes Dev. 11:2347–2358. 1997. View Article : Google Scholar : PubMed/NCBI
2.	Dantzer F, de La Rubia G, Menissier-De Murcia J, Hostomsky Z, de Murcia G and Schreiber V: Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1. Biochemistry. 39:7559–7569. 2000. View Article : Google Scholar : PubMed/NCBI
3.	Trucco C, Oliver FJ, de Murcia G and Menissier-de Murcia J: DNA repair defect in poly(ADP-ribose) polymerase-deficient cell lines. Nucleic Acids Res. 26:2644–2649. 1998. View Article : Google Scholar : PubMed/NCBI
4.	Menissier de Murcia J, Ricoul M, Tartier L, et al: Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. EMBO J. 22:2255–2263. 2003.PubMed/NCBI
5.	Ame JC, Rolli V, Schreiber V, et al: PARP-2, a novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase. J Biol Chem. 274:17860–17868. 1999. View Article : Google Scholar : PubMed/NCBI
6.	Juarez-Salinas H, Sims JL and Jacobson MK: Poly(ADP-ribose) levels in carcinogen-treated cells. Nature. 282:740–741. 1979. View Article : Google Scholar : PubMed/NCBI
7.	Brochu G, Duchaine C, Thibeault L, Lagueux J, Shah GM and Poirier GG: Mode of action of poly(ADP-ribose) glycohydrolase. Biochim Biophys Acta. 1219:342–350. 1994. View Article : Google Scholar : PubMed/NCBI
8.	Lin W, Ame JC, Aboul-Ela N, Jacobson EL and Jacobson MK: Isolation and characterization of the cDNA encoding bovine poly(ADP-ribose) glycohydrolase. J Biol Chem. 272:11895–11901. 1997. View Article : Google Scholar : PubMed/NCBI
9.	Schreiber V, Ame JC, Dolle P, et al: Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J Biol Chem. 277:23028–23036. 2002. View Article : Google Scholar : PubMed/NCBI
10.	Dantzer F, Schreiber V, Niedergang C, et al: Involvement of poly(ADP-ribose) polymerase in base excision repair. Biochimie. 81:69–75. 1999. View Article : Google Scholar : PubMed/NCBI
11.	Sims JL, Berger SJ and Berger NA: Poly(ADP-ribose) Polymerase inhibitors preserve nicotinamide adenine dinucleo-tide and adenosine 5′-triphosphate pools in DNA-damaged cells: mechanism of stimulation of unscheduled DNA synthesis. Biochemistry. 22:5188–5194. 1983.PubMed/NCBI
12.	Andrabi SA, Kim NS, Yu SW, et al: Poly(ADP-ribose) (PAR) polymer is a death signal. Proc Natl Acad Sci USA. 103:18308–18313. 2006. View Article : Google Scholar : PubMed/NCBI
13.	Jacobson EL, Smith JY, Wielckens K, Hilz H and Jacobson MK: Cellular recovery of dividing and confluent C3H10T1/2 cells from N-methyl-N’-nitro-N-nitrosoguanidine in the presence of ADP-ribosylation inhibitors. Carcinogenesis. 6:715–718. 1985.PubMed/NCBI
14.	Park SD, Kim CG and Kim MG: Inhibitors of poly(ADP-ribose) polymerase enhance DNA strand breaks, excision repair, and sister chromatid exchanges induced by alkylating agents. Environ Mutagen. 5:515–525. 1983. View Article : Google Scholar : PubMed/NCBI
15.	Boulton S, Pemberton LC, Porteous JK, et al: Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. Br J Cancer. 72:849–856. 1995. View Article : Google Scholar : PubMed/NCBI
16.	Rankin PW, Jacobson EL, Benjamin RC, Moss J and Jacobson MK: Quantitative studies of inhibitors of ADP-ribosylation in vitro and in vivo. J Biol Chem. 264:4312–4317. 1989.PubMed/NCBI
17.	Banasik M, Komura H, Shimoyama M and Ueda K: Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. J Biol Chem. 267:1569–1575. 1992.PubMed/NCBI
18.	Kjellen E, Pero RW, Brun E, et al: A phase I/II evaluation of metoclopramide as a radiosensitiser in patients with inoperable squamous cell carcinoma of the lung. Eur J Cancer. 31A:2196–2202. 1995. View Article : Google Scholar : PubMed/NCBI
19.	Rouleau M, Patel A, Hendzel MJ, Kaufmann SH and Poirier GG: PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 10:293–301. 2010. View Article : Google Scholar : PubMed/NCBI
20.	Farmer H, McCabe N, Lord CJ, et al: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 434:917–921. 2005. View Article : Google Scholar : PubMed/NCBI
21.	Bryant HE, Schultz N, Thomas HD, et al: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 434:913–917. 2005. View Article : Google Scholar : PubMed/NCBI
22.	Donawho CK, Luo Y, Penning TD, et al: ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 13:2728–2737. 2007. View Article : Google Scholar : PubMed/NCBI
23.	Norquist B, Wurz KA, Pennil CC, et al: Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol. 29:3008–3015. 2011. View Article : Google Scholar : PubMed/NCBI
24.	Hutchinson L: Targeted therapies: PARP inhibitor olaparib is safe and effective in patients with BRCA1 and BRCA2 mutations. Nat Rev Clin Oncol. 7:5492010. View Article : Google Scholar : PubMed/NCBI
25.	Tutt A, Robson M, Garber JE, et al: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 376:235–244. 2010. View Article : Google Scholar
26.	Audeh MW, Carmichael J, Penson RT, et al: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 376:245–251. 2010. View Article : Google Scholar
27.	Fujihara H, Ogino H, Maeda D, et al: Poly(ADP-ribose) glycohydrolase deficiency sensitizes mouse ES cells to DNA damaging agents. Curr Cancer Drug Targets. 9:953–962. 2009. View Article : Google Scholar : PubMed/NCBI
28.	Hanai S, Kanai M, Ohashi S, et al: Loss of poly(ADP-ribose) glycohydrolase causes progressive neurodegeneration in Drosophila melanogaster. Proc Natl Acad Sci USA. 101:82–86. 2004. View Article : Google Scholar : PubMed/NCBI
29.	Koh DW, Lawler AM, Poitras MF, et al: Failure to degrade poly(ADP-ribose) causes increased sensitivity to cytotoxicity and early embryonic lethality. Proc Natl Acad Sci USA. 101:17699–17704. 2004. View Article : Google Scholar : PubMed/NCBI
30.	Min W, Cortes U, Herceg Z, Tong WM and Wang ZQ: Deletion of the nuclear isoform of poly(ADP-ribose) glycohydrolase (PARG) reveals its function in DNA repair, genomic stability and tumorigenesis. Carcinogenesis. 31:2058–2065. 2010. View Article : Google Scholar : PubMed/NCBI
31.	Ame JC, Fouquerel E, Gauthier LR, et al: Radiation-induced mitotic catastrophe in PARG-deficient cells. J Cell Sci. 122:1990–2002. 2009. View Article : Google Scholar : PubMed/NCBI
32.	Tentori L, Leonetti C, Scarsella M, et al: Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide. Eur J Cancer. 41:2948–2957. 2005. View Article : Google Scholar : PubMed/NCBI
33.	Fathers C, Drayton RM, Solovieva S and Bryant HE: Inhibition of poly(ADP-ribose) glycohydrolase (PARG) specifically kills BRCA2-deficient tumor cells. Cell Cycle. 11:990–997. 2012. View Article : Google Scholar : PubMed/NCBI
34.	Kickhoefer VA, Siva AC, Kedersha NL, et al: The 193-kD vault protein, VPARP, is a novel poly(ADP-ribose) polymerase. J Cell Biol. 146:917–928. 1999. View Article : Google Scholar : PubMed/NCBI
35.	Smith S, Giriat I, Schmitt A and de Lange T: Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. Science. 282:1484–1487. 1998. View Article : Google Scholar : PubMed/NCBI
36.	Takahashi K, Greenberg JH, Jackson P, Maclin K and Zhang J: Neuroprotective effects of inhibiting poly(ADP-ribose) synthetase on focal cerebral ischemia in rats. J Cereb Blood Flow Metab. 17:1137–1142. 1997. View Article : Google Scholar : PubMed/NCBI
37.	Abdelkarim GE, Gertz K, Harms C, et al: Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke. Int J Mol Med. 7:255–260. 2001.
38.	Shieh WM, Ame JC, Wilson MV, et al: Poly(ADP-ribose) polymerase null mouse cells synthesize ADP-ribose polymers. J Biol Chem. 273:30069–30072. 1998. View Article : Google Scholar : PubMed/NCBI
39.	Pinsky SD, Tew KD, Smulson ME and Woolley PV III: Modification of L1210 cell nuclear proteins by 1-methyl-1-nitrosourea and 1-methyl-3-nitro-1-nitrosoguanidine. Cancer Res. 39:923–928. 1979.PubMed/NCBI
40.	Kim MY, Mauro S, Gevry N, Lis JT and Kraus WL: NAD⁺-dependent modulation of chromatin structure and transcription by nucleosome binding properties of PARP-1. Cell. 119:803–814. 2004.
41.	Zhou Y, Feng X and Koh DW: Synergistic cytotoxicity of N-methyl-N’-nitro-N-nitrosoguanidine and absence of poly(ADP-ribose) glycohydrolase involves chromatin decondensation. Int J Oncol. 39:121–127. 2011.
42.	Zhou Y, Feng X and Koh DW: Enhanced DNA accessibility and increased DNA damage induced by the absence of poly(ADP-ribose) hydrolysis. Biochemistry. 49:7360–7366. 2010. View Article : Google Scholar : PubMed/NCBI
43.	Zhou Y, Feng X and Koh DW: Activation of cell death mediated by apoptosis-inducing factor due to the absence of poly(ADP-ribose) glycohydrolase. Biochemistry. 50:2850–2859. 2011. View Article : Google Scholar : PubMed/NCBI
44.	Jacobson MK and Jacobson EL: Discovering new ADP-ribose polymer cycles: protecting the genome and more. Trends Biochem Sci. 24:415–417. 1999. View Article : Google Scholar : PubMed/NCBI
45.	Feng X, Zhou Y, Proctor AM, Hopkins MM, Liu M and Koh DW: Silencing of apoptosis-inducing factor and poly(ADP-ribose) glycohydrolase reveals novel roles in breast cancer cell death after chemotherapy. Mol Cancer. 11:482012. View Article : Google Scholar : PubMed/NCBI